Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 9:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 73 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Atorvastatin 80 mg Clear all
Completed Phase 3 Interventional Results available

Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study

NCT01516879
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Evolocumab, Placebo, Atorvastatin, Ezetimibe, Diet Only
Biological · Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
905 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
41
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Sep 22, 2026, 9:53 AM EDT
Terminated Phase 2 Interventional Results available

Mission Connect Mild Traumatic Brain Injury (TBI) Integrated Clinical Protocol

NCT01013870
View directory record Official record
Conditions
Traumatic Brain Injury, Post-traumatic Stress Disorder
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Sep 22, 2026, 9:53 AM EDT
Completed Phase 2 Interventional

A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg

NCT02659397
View directory record Official record
Conditions
Hyperlipidemia
Interventions
ETC-1002, Atorvastatin, Placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
19
States / cities
Anaheim, California • Los Angeles, California • Northridge, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Sep 22, 2026, 9:53 AM EDT
Completed Early Phase 1 Interventional

A Pre-Op Window Study Evaluating Anti-Proliferative Effects of Atorvastatin on the Endometrium

NCT02767362
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Atorvastatin
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 6, 2020 · Synced Sep 22, 2026, 9:53 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma

NCT00185731
View directory record Official record
Conditions
Leukemia, Lymphoma, Non-Hodgkin
Interventions
Atorvastatin
Drug
Lead sponsor
Dean Felsher
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Sep 22, 2026, 9:53 AM EDT
Completed Phase 2 Interventional Results available

Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease

NCT00296374
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Rosuvastatin, Atorvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
29
States / cities
Avondale, Arizona • Phoenix, Arizona • Jonesboro, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2011 · Synced Sep 22, 2026, 9:53 AM EDT
Active, not recruiting Phase 1 Interventional

A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies

NCT03560882
View directory record Official record
Conditions
Malignant Disease, Solid Tumor, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Cancer, Relapsed Hematologic Malignancy
Interventions
Atorvastatin
Drug
Lead sponsor
Joaquina Baranda
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Fairway, Kansas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 22, 2026, 9:53 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Prothrombotic Inflammatory Markers in Women With Metabolic Syndrome - Effect of Atorvastatin

NCT01785615
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Atorvastatin, Placebo
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Sep 22, 2026, 9:53 AM EDT
Enrolling by invitation Phase 2 Interventional

Multi-Arm Multi-Stage Adaptive Platform Trial (APT) for the Acute Treatment of Traumatic Brain Injury

NCT05826912
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Atorvastatin Calcium, Minocycline Hydrochloride, Candesartan Cilexetil, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
18
States / cities
San Francisco, California • Indianapolis, Indiana • Lexington, Kentucky + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 22, 2026, 9:53 AM EDT
Recruiting Phase 2 Interventional

Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)

NCT05483010
View directory record Official record
Conditions
Clonal Cytopenia of Undetermined Significance, Myelodysplastic Syndromes
Interventions
Atorvastatin, Rosuvastatin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 22, 2026, 9:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Lomitapide in Healthy Subjects.

NCT02080455
View directory record Official record
Conditions
Effect of Atorvastatin on the Pharmacokinetics of Lomitapide
Interventions
lomitapide, Atorvastatin
Drug
Lead sponsor
Aegerion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Sep 22, 2026, 9:53 AM EDT
Completed Phase 3 Interventional Results available

Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial)

NCT01528709
View directory record Official record
Conditions
Saphenous Vein Graft Disease
Interventions
Atorvastatin 80 mg daily, Atorvastatin 10 mg daily
Drug
Lead sponsor
Boca Raton Regional Hospital
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Sep 22, 2026, 9:53 AM EDT
Completed Phase 3 Interventional Results available

Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)

NCT01730040
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Atorvastatin, Ezetimibe, Rosuvastatin, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
56
States / cities
Mobile, Alabama • Chandler, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2015 · Synced Sep 22, 2026, 9:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Systems Biological Assessment of Statin Effect on Vaccine Responses

NCT06024096
View directory record Official record
Conditions
Vaccine Response
Interventions
Atorvastatin, Quadrivalent seasonal influenza vaccine
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 22, 2026, 9:53 AM EDT
Completed Phase 3 Interventional Results available

Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood

NCT00300469
View directory record Official record
Conditions
Mixed Dyslipidemia, Coronary Heart Disease, Dyslipidemia
Interventions
ABT-335, Atorvastatin, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 2, 2009 · Synced Sep 22, 2026, 9:53 AM EDT
Completed Phase 3 Interventional Results available

CRESTOR Athero Imaging Head to Head IVUS Study

NCT00620542
View directory record Official record
Conditions
Coronary Atherosclerosis
Interventions
Rosuvastatin, Atorvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
2,333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
97
States / cities
Huntsville, Alabama • Los Angeles, California • Mountain View, California + 94 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2012 · Synced Sep 22, 2026, 9:53 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

ARREST PAD (Peripheral Arterial Disease)

NCT00153166
View directory record Official record
Conditions
Arterial Occlusive Disease, Intermittent Claudication, Insulin Resistance
Interventions
atorvastatin and pioglitazone, atorvastatin/placebo, pioglitazone/placebo, placebo/placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 85 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Sep 22, 2026, 9:53 AM EDT
Terminated Not applicable Interventional Results available

Effects of Statins on Lower Extremity Arterial Function Assessed by Magnetic Resonance Imaging

NCT00770679
View directory record Official record
Conditions
Diabetes
Interventions
lipitor
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Sep 22, 2026, 9:53 AM EDT
Terminated Phase 3 Interventional Results available

Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes

NCT02850081
View directory record Official record
Conditions
Carotid Artery Stenosis, Strokes
Interventions
Statin, Atorvastatin, Placebo
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
7
States / cities
Ridgewood, New Jersey • Albany, New York • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 22, 2026, 9:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple-Dose Pharmacokinetic Interaction Study Between ABT-335, Atorvastatin and Ezetimibe

NCT00681525
View directory record Official record
Conditions
Pharmacokinetics
Interventions
ABT-335, Atorvastatin, Ezetimibe
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 18, 2010 · Synced Sep 22, 2026, 9:53 AM EDT
Completed Phase 4 Interventional

Do HMG CoA Reductase Inhibitors Affect Abeta Levels?

NCT00303277
View directory record Official record
Conditions
Alzheimer's Disease, Aging
Interventions
simvastatin, pravastatin
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 90 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 12, 2010 · Synced Sep 22, 2026, 9:53 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Atorvastatin as a Potential Adjunct to Misoprostol for Termination of Pregnancy

NCT05342974
View directory record Official record
Conditions
Abortion Early
Interventions
Atorvastatin, Misoprostol
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 22, 2026, 9:53 AM EDT
Terminated Phase 3 Interventional Results available

Ezetimibe in Patients Hypo-responsive to Statins

NCT00965055
View directory record Official record
Conditions
High Cholesterol, Coronary Artery Disease
Interventions
Ezetimibe, Atorvastatin
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Sep 22, 2026, 9:53 AM EDT
Terminated Phase 4 Interventional Results available

Effects of Atorvastatin on Myonecrosis

NCT00344019
View directory record Official record
Conditions
Coronary Disease
Interventions
Placebo Oral Tablet, Atorvastatin 80mg, Screening
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 1, 2018 · Synced Sep 22, 2026, 9:53 AM EDT